Untitled
esquerda


Leia a Última Edição!

II Serie Volume 34 Number 4
April 2021

E-ALERT:

menu esquerda
 
   
 
 
 
 


  1- Factors of recurrence of intraepithelial lesions of the uterine cervix.

2- Duodenoscopy and endoscopic retrograde cholangiopancreatography (ERCP) in the diagnosis of biliary and pancreatic pathology.

3- Mephedrone (?Meow Meow?), The New Designer Drug of Abuse: Pharmacokinetics, Pharmacodynimics and Clinical and Forensic Issues

4- Natural history of fetal pyelocaliectasia.

5- Antidepressant drugs.

6- Erysipelas.

7- Pressure ulcer management--Evidence-based interventions.

8- Traumatic Brain Injury: Integrated Approach

9- Genital ulcers caused by sexually transmitted diseases: current therapies, diagnosis and their relevance in HIV pandemy.

10- Current management of gout.

11- Livedo vasculitis.

12- Tarlov's cyst: definition, etiopathogenesis, propaedeutic and treatment.

13- Antibiotic treatment of uncomplicated cystitis in non-pregnant women up to menopause.

14- Urolithiasis and renal colic. Therapeutic approach in urology.

15- Uterine inversion.

16- Surgical basic skills: surgical sutures.

17- Intrahepatic cholestasis in pregnancy. Its etiopathogenesis, prognosis and therapy.

18- Necrotizing Pneumonia ? A Rare Complication

19- Shoulder dystocia: an obstetrical emergency.

20- Antihypertensive treatment in pregnancy.

 
   

Inherited Retinal Degenerations in Portugal: Addressing the Unmet Needs



Inherited retinal dystrophies/ degenerations (IRDs) are a clinically and genetically heterogenous group of rare eye diseases. Despite their low prevalence (~1:3000 individuals), IRDs are an important cause of severe visual impairment and blindness in children and young adults. Over the past three decades, major advances in molecular biology and human genetics have contributed to uncover the molecular basis of these disorders. Most excitingly, treatment of a particular form of congenital retinal degeneration is now possible. In December 2017, the Food and Drug Administration (FDA) approved voretigene neparvovec (Luxturna, Spark Therapeutics Inc.) to treat RPE65 mutation-associated retinal degeneration, which inevitably progresses to complete blindness by the third/fourth decade of life.

Click here for the full paper.